Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
about
A comprehensive review on metabolic syndromeLipid-lowering efficacy of atorvastatinLipid lowering efficacy of atorvastatinEffects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefitOrigin and therapy for hypertriglyceridaemia in type 2 diabetesThyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.Treatment of dyslipidaemia in HIV-infected persons.Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.Dyslipidemia in older adults.Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives.The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndromeDyslipidemic drugs in metabolic syndrome.Efficacy and safety of rosuvastatin in the management of dyslipidemiaOne-Year Clinical Outcomes among Patients with Metabolic Syndrome and Acute Myocardial InfarctionAtherogenic dyslipidemia.Demystifying the management of hypertriglyceridaemia.Pharmacological treatment and therapeutic perspectives of metabolic syndrome.Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.Rosuvastatin: achieving cholesterol targets.Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin.Normalization of metabolic syndrome using fenofibrate, metformin or their combination.Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1.Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients.Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome.Inulin-type fructans have no significant beneficial effects on lipid or glucose metabolism.Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents.
P2860
Q21284500-78881307-1AE0-45B8-90D1-CC99EC0E5FE1Q24187301-88B83C2A-4852-408D-933B-EE18254795BBQ24202363-25E3768D-97FF-4C51-A54B-5000C1301233Q24650533-E84E7343-BFA6-4500-912A-C5A92360D01EQ26824004-5E35DA00-EC99-4E05-9E94-BEB18AA2A36AQ26995671-C3720D5C-9A15-45B8-8D0E-E45C6DB06C08Q33691594-51069EC4-23FB-47D7-9346-DDD17D63313DQ34757003-2E602E09-EFAE-4B62-97A3-14582A6A6B78Q36222023-5E412EA1-23E1-435E-AE5A-CD8BCDD59F46Q36249934-9D403C6A-5628-4179-B9FE-CDC5A17AE741Q36540305-F0833EA6-5CB2-4D6E-8028-999188A8995AQ36641901-1B8B9835-0E30-4EFF-8A4D-424F38B1FABAQ36752067-0C6E48F5-49CB-4B1F-8200-9C49A6C4B9F0Q36807515-63F1DC27-EF97-47B9-B3F1-C9F3CFCBF613Q37016008-5D56BD12-21D6-4132-BC51-E228F6EC4A5AQ37167517-A93C0858-9F64-4323-AC17-99D496935A70Q37168641-63693D29-5028-4BDD-900A-4F6962E54B8FQ37413996-A921E034-E4C8-4850-BE04-B90E6D7AD123Q38141575-035F3081-31BE-4D30-927C-AA1199206179Q38262435-E4A9848D-7BFC-4F9C-A5EC-0D4D43FBB8D7Q39774154-98C0A1F0-A995-47B7-8E0D-188F53BAD470Q40426760-67A59079-47B0-4DA3-8C91-D9C56D88055FQ43165990-3EFF658F-32CA-4561-A15E-DAB02DCA08EDQ46688401-A0EC9A4A-B0AB-4F24-9184-930CFE8A6D64Q46821545-FF1600BB-5C2D-4A7B-9BE3-2947BA67F309Q46959415-453D1FDF-9994-4731-AC5E-2987C4F47DCEQ47377600-6F0D01B6-81A6-4FB2-92ED-A74F892A139EQ50108375-BCFBE141-A576-4E6A-A71B-EB24ED770E6BQ51304354-6E7DD99C-CF0F-4D74-ADED-6FCDB1EE30DFQ51838614-C14BC07B-6C17-4289-923F-945331DDB4BCQ51900207-A19C3AE9-0715-400C-ACAD-66471F3AC396
P2860
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@en
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@nl
type
label
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@en
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@nl
prefLabel
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@en
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@nl
P2093
P921
P1476
Effects of rosuvastatin, atorv ...... ics of the metabolic syndrome.
@en
P2093
Donald B Hunninghake
Harold E Bays
James W Blasetto
Peter H Jones
Prakash C Deedwania
STELLAR Study Group
Valerie A Cain
P304
P356
10.1016/J.AMJCARD.2004.09.034
P407
P577
2005-02-01T00:00:00Z